Article Text
Statistics from Altmetric.com
Key points
Dupilumab, a monoclonal antibody that inhibits interleukin-4 and interleukin-13 signalling, is licensed in the UK for a range of conditions including atopic dermatitis and asthma.
A placebo-controlled trial assessed the effect of dupilumab in people with chronic obstructive pulmonary disease who had an eosinophil count ≥300 per microlitre and were at an increased risk of an exacerbation.
The annualised rate of moderate or severe exacerbations was 0.78 with dupilumab and 1.1 with placebo.
An injection of dupilumab given every 2 weeks for 52 weeks in addition to triple inhaler therapy to people with chronic obstructive pulmonary disease (COPD) who had an eosinophil count ≥300 per microlitre and who were at an increased risk of an exacerbation reduced the annualised rate of moderate or severe exacerbations by 0.32 compared with placebo.1
Overview
An international multicentre phase 3 double-blind randomised controlled trial evaluated the effects of treatment with dupilumab on …
Footnotes
Contributors DTB Team.
Provenance and peer review Commissioned; internally peer reviewed.